To conclude, ABCG2 34G>A and ABCB1 3435C>T are strong predictors for the development of new CNS metastases in patients treated with osimertinib for EGFRm+ NSCLC who have no documented CNS metastases. Here, ABCG2 is linked to non-small cell lung carcinoma.